Global Non-Alcoholic Steatohepatitis (NASH) Pipeline Therapeutics Report 2019

News provided by

Jan 23, 2019, 09:15 ET

DUBLIN, Jan. 23, 2019 /PRNewswire/ --

The "Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

"Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Non-Alcoholic Steatohepatitis (NASH) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical
Non-clinical
Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Non-Alcoholic Steatohepatitis (NASH)

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Non-Alcoholic Steatohepatitis (NASH)

The report assesses the active Non-Alcoholic Steatohepatitis (NASH) pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

The report provides a snapshot of the pipeline development for the Non-Alcoholic Steatohepatitis (NASH)
The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Non-Alcoholic Steatohepatitis (NASH)
The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Non-Alcoholic Steatohepatitis (NASH)
The report also covers the dormant and discontinued pipeline projects related to the Non-Alcoholic Steatohepatitis (NASH)

Reasons to Buy

Establish comprehensive understanding of the pipeline activity across this Non-Alcoholic Steatohepatitis (NASH) to formulate effective R&D strategies
Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Non-Alcoholic Steatohepatitis (NASH) therapeutics
Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Key Topics Covered:

1. Report Introduction

2. Non-Alcoholic Steatohepatitis (NASH) Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Non-Alcoholic Steatohepatitis (NASH)

4. Comparative Analysis

5. Products in Clinical Stage

Product Description
Research and Development
Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

Product Description
Research and Development
Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type

8. Inactive Products

Product Description
Research and Development
Product Development Activities

Companies Mentioned

Albreo Pharma Inc
Allergan Plc
Alnylam Pharmaceuticals Inc
Amunix Operating Inc
Aquinox Pharmaceuticals Inc
Ardelyx Inc
Arisaph Pharmaceuticals Inc
ARMO Biosciences Inc
AstraZeneca Plc
Betagenon AB
BioLineRx Ltd
BiOrion Technologies BV
Bird Rock Bio Inc
Boehringer Ingelheim GmbH
BLR Bio LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/56zrt6/global?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets